Human monoclonal antibody fab fragments directed against hcv...

C - Chemistry – Metallurgy – 12 – N

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C12N 15/13 (2006.01) A61K 39/395 (2006.01) A61K 48/00 (2006.01) A61P 31/14 (2006.01) C07K 16/10 (2006.01) C12N 15/63 (2006.01) G01N 33/576 (2006.01)

Patent

CA 2474801

The invention refers to a human antibody, or its functional fragments, directed against the HCV E2 glycoprotein, able to have a neutralizing activity in vivo; a composition for anti-HCV therapy comprising in a therapeutically effective amount the antibody; a composition for topical use in gel, creme, ointment and ovule formulations; the use of the antibody for validating anti- HCV vaccines.

La présente invention concerne un anticorps humain, ou ses fragments fonctionnels, dirigés contre la glycoprotéine VHC/E2, capable d'avoir un effet d'activité de neutralisation in vivo ; une composition pour la thérapie anti-VHC comprenant en quantité thérapeutiquement efficace ledit anticorps ; une composition d'usage topique sous forme de gel, de crème, d'onguent et de comprimé vaginal ; l'utilisation dudit anticorps pour la validation de vaccin anti-VCH.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Human monoclonal antibody fab fragments directed against hcv... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human monoclonal antibody fab fragments directed against hcv..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human monoclonal antibody fab fragments directed against hcv... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1813808

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.